For all investor queries, please contact info@vasomune.com.
Latest News
Vasomune and AnGes Announce First Patient Enrolled in Phase 2a Clinical Study Evaluating AV-001 for the Treatment of Severe COVID-19 Disease
Vasomune Therapeutics doses first patient in Phase 2a clinical study to evaluate AV-001 in patients hospitalized with severe COVID-19 disease. January 18, 2022 08:00 AM
January 18, 2022
No Comments
Vasomune Announces Government Financial Support for the Development of COVID-19 Therapeutic
Vasomune Receives a US $6.4 Million PRMRP Grant from the US Department of Defense and up to $2.8 Million from NRC IRAP to Support the
November 8, 2021
No Comments
Vasomune Announces Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy
Vasomune Announces Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy AV-001 was Safe and Well-Tolerated in Healthy Volunteers Vasomune plans to initiate
March 25, 2021
No Comments
Vasomune is Pleased to Announce the Government of Canada’s Investment in AV-001 Targeting COVID-19
Vasomune is very pleased to announce that the company has received a substantial investment on behalf of the Government of Canada through the National Research
March 17, 2021
No Comments